Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ Β-carotene) for Infertile Males

NCT ID: NCT06100432

Last Updated: 2025-03-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-11
• Study Completion Date: 2025-10-31

Brief Summary

Infertility is defined as the inability of a couple to get pregnant after one year of regular and unprotected sexual intercourse. Although it is not a life-threatening condition, infertile couple often suffer from mental health issues, including depression and low self-esteem that may impact their Quality of Life (QoL). Male factors contribute to a half of the underlying causes of infertility and semen analysis play a vital role in investigation of the fertility status of the male partners. By performing semen analysis, we could predict the chance of a couple to conceive.

Male infertility treatments include surgery, hormonal treatment and also assisted reproductive techniques, such as intra uterine insemination and in vitro fertilization that may lead to a financial burden for infertile couple. For facing this issue, traditional or herbal medicine and antioxidants are often be used as an alternative way by many infertile couples. One of the traditional medicines used in Indonesia and other Southeast-Asia Countries for infertility cases is Eurycoma longifolia or Pasak Bumi.

Based on previous studies in animals, Eurycoma longifolia could improve Testosterone and may improve sperm parameters, even though there are very few studies in human including in Indonesia. Antioxidants (multivitamins) are also routinely given to the infertile men as they could protect sperm damages from oxidative stress and may in advanced improve sperm quantity and quality. Our study aims to compare the effect of Eurycoma longifolia, Multivitamins and the combination on sperm parameters and also reproductive hormones of the infertile males.

Detailed Description

Study population will be idiopathic infertile males who come to the study site. Those who meet inclusion and exclusion criteria will be randomized into three groups (30 subjects each group). Therefore, it will be total 90 subjects planned to be enrolled in the study.

There will be 3 groups of treatment:

Treatment 1: Eurycoma longifolia (DLBS5055) 200mg caplet Treatment 2: 2 caplets of Multivitamin (each caplet consists of Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU) Treatment 3: Eurycoma longifolia (DLBS5055) 200mg caplet and 2 caplets of Multivitamin (each caplet consists of Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)

Because this study will be double-blind randomized controlled trial, each subject still received 3 caplets (one caplet of DLBS5055 or its placebo and two caplets of multivitamin or their placebo), based on treatment group where the subject will be allocated. DLBS5055 caplet or its placebo will be administered once daily 30 minutes after lunch, whereas two multivitamin caplets will be administered once daily 30 minutes after breakfast.

Eligible subjects will be randomly allocated to receive either Treatment 1, Treatment 2 or Treatment 3 for 12 weeks. Subjects will be instructed to come to the clinic every 6-week interval throughout the 12-week study period (at the end of Week 6 and at the end of Week 12) for treatment evaluation. The semen analysis and reproductive hormonal evaluation will be performed at Baseline and at the End of therapy (Week 12). Additional testosterone level monitoring will be performed in the middle of study period (at the end of Week 6). Adverse events will be monitored at baseline and every follow-up visit including End of study (Week 12).

Conditions

Male Infertility

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment 1

DLBS5055 \& Placebo Multivitamin

Group Type: EXPERIMENTAL

DLBS5055 200mg

Intervention Type: DRUG

1x1 caplet

Placebo Multivitamin

Intervention Type: DRUG

1x2 caplets

Treatment 2

Multivitamin (Vitamin C 1000mg + Vitamin E 200IU + Beta Carotene 20000IU) \& Placebo DLBS5055

Group Type: ACTIVE_COMPARATOR

Placebo DLBS5055

Intervention Type: DRUG

1x1 caplet

Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)

Intervention Type: DRUG

1x2 caplets

Treatment 3

DLBS5055 \& Multivitamin (Vitamin C 1000mg + Vitamin E 200IU + Beta Carotene 20000IU)

Group Type: EXPERIMENTAL

DLBS5055 200mg

Intervention Type: DRUG

1x1 caplet

Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)

Intervention Type: DRUG

1x2 caplets

Interventions

DLBS5055 200mg

1x1 caplet

Intervention Type: DRUG

Placebo DLBS5055

1x1 caplet

Intervention Type: DRUG

Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)

1x2 caplets

Intervention Type: DRUG

Placebo Multivitamin

1x2 caplets

Intervention Type: DRUG

Other Intervention Names

Herbapoten; Placebo Herbapoten; Oxyvit C+; Placebo Oxyvit C+

Eligibility Criteria

Inclusion Criteria

1. Male with idiopathic infertility

2. Age 20-45 years

3. Married and try to conceive.

4. Being registered with the Indonesian Social Health Insurance Administration Body (BPJS).

5. Has sperm concentration more than 5 million per mL.

6. Has testosterone level between 350-600 ng/dl.

7. Withdraw from any antioxidant treatment for at least 14 days before the enrollment of the study.

8. Able to understand and provide Informed Consent

Exclusion Criteria

1. Has a varicocele and other metabolic diseases such as diabetes mellitus.

2. Has a history of surgery or injury in the genital region.

3. Has a history of acute and chronic inflammatory diseases.

4. Has a known allergy to any ingredients of the active or placebo material of the tested drugs (Eurycoma longifolia, Vitamin C, Vitamin E and Beta-carotene).

5. Has a history of hormonal therapy in the last 6 months.

6. Consumes any herbal or traditional medicine.

7. Consumes any medicine contains steroid.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Dexa Medica Group

INDUSTRY

Sponsor Role: collaborator

Duta Wacana Christian University

OTHER

Sponsor Role: lead

Responsible Party

dr. Seso Sulijaya Suyono, Sp.And

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Seso S Suyono, MD

Role: PRINCIPAL_INVESTIGATOR

Duta Wacana Christian University

Locations

Laboratorium Klinik Pramita

Yogyakarta, Special Region of Yogyakarta, Indonesia

Countries

Indonesia

References

Zohman GL, Watts HG. Is a routine radiological consultation cost-effective for pediatric orthopedic radiographs? J Pediatr Orthop. 1998 Jul-Aug;18(4):549-51.

Reference Type: BACKGROUND

PMID: 9661871 (View on PubMed)

Moskovko VM. [Circadian rhythm of blood clotting processes]. Voen Med Zh. 1986 May;(5):57. No abstract available. Russian.

Reference Type: BACKGROUND

PMID: 3739276 (View on PubMed)

Zuckerman M. P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. Neuropsychobiology. 1993;28(1-2):30-6. doi: 10.1159/000118996.

Reference Type: BACKGROUND

PMID: 8255407 (View on PubMed)

Senciall IR, Rahal S, Sethumadhavan K. Solubilisation and fractional precipitation of a steroid alpha-ketol oxidase. J Steroid Biochem. 1985 Dec;23(6A):1083-5. doi: 10.1016/0022-4731(85)90072-x.

Reference Type: BACKGROUND

PMID: 4094415 (View on PubMed)

Other Identifiers

UST00223

Identifier Type: -

Identifier Source: org_study_id